BTIG Research Reiterates Buy Rating for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a research note issued to investors on Friday,Benzinga reports. They presently have a $88.00 target price on the medical instruments supplier’s stock. BTIG Research’s price objective would indicate a potential upside of 7.30% from the stock’s current price.

A number of other brokerages have also weighed in on HAE. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. JPMorgan Chase & Co. raised their price objective on shares of Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. Raymond James Financial reiterated an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a report on Friday, November 14th. Finally, Citigroup lowered their target price on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $84.10.

Haemonetics Price Performance

HAE stock opened at $82.01 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. The company’s 50-day moving average is $77.66 and its 200-day moving average is $65.92. The stock has a market capitalization of $3.84 billion, a PE ratio of 23.98, a price-to-earnings-growth ratio of 1.55 and a beta of 0.29. Haemonetics has a 1 year low of $47.31 and a 1 year high of $87.32.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. The business had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The firm’s revenue was down 5.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities research analysts expect that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its position in Haemonetics by 372.8% in the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after purchasing an additional 1,678,630 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Haemonetics by 4,296.3% in the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after acquiring an additional 755,592 shares in the last quarter. Norges Bank bought a new position in shares of Haemonetics in the second quarter valued at approximately $36,822,000. Invenomic Capital Management LP increased its position in shares of Haemonetics by 1,691.5% during the third quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock valued at $24,288,000 after acquiring an additional 470,502 shares during the last quarter. Finally, SG Capital Management LLC lifted its holdings in Haemonetics by 92.5% during the second quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock worth $67,663,000 after acquiring an additional 435,660 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Acquisition adds next‑generation large‑bore vascular closure tech (PerQseal Elite), broadening Haemonetics’ product set for structural heart and endovascular procedures. This expansion supports revenue cross‑sell and addresses a growing procedural market. Article Title
• Positive Sentiment: Deal strengthens Haemonetics’ vascular closure market presence and positions it in a niche (sutureless, bioabsorbable closure for up to 26F) that’s relevant to structural‑heart device growth. This is a clear strategic tuck‑in that could accelerate top‑line growth if adoption scales. Article Title
• Positive Sentiment: Analyst and market sentiment supportive: BTIG reaffirmed a “buy” with an $88 price target, signaling incremental analyst confidence that could help investor appetite. Article Title
• Positive Sentiment: Independent research notes Haemonetics’ streak of earnings surprises and suggests the company has the mix to beat again, which can lift sentiment alongside M&A news. Article Title
• Neutral Sentiment: Multiple outlets are reporting the deal and confirming the headline terms (up to €185M), underscoring that the transaction is public and priced; broader market reaction will depend on integration pacing and revenue contribution over time. Article Title
• Negative Sentiment: Potential risks: integration/execution risk and any financing impact (Haemonetics’ balance sheet and leverage could be affected depending on how the deal was funded). These factors could weigh on near‑term margins or sentiment if costs or slower adoption emerge.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.